Ala-Seppälä Henna Maria, Ukkonen Mika Tapani, Laurikka Jari Olavi, Khan Jahangir Ari
Department of Cardio-Thoracic Surgery, Heart Hospital, Tampere University Hospital, Tampere, Finland.
Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
J Thorac Dis. 2024 Jul 30;16(7):4329-4339. doi: 10.21037/jtd-24-308. Epub 2024 Jul 11.
The incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), after lung cancer resections varies in the literature, and there is limited evidence regarding the optimal duration of thromboprophylaxis. This study aimed at determining the early and long-term occurrence of thromboembolic complications in patients who received in-hospital thromboprophylaxis and underwent resective surgery for lung cancer.
The study included all patients who underwent lung cancer surgery at Tampere University Hospital between 2004 and 2016. Postoperative thromboprophylaxis was administered for the duration of the hospitalization. Data on subsequent episodes of VTE and survival were obtained from national registries. The results were compared to a demographically matched reference population.
The study comprised 435 patients and 4,338 individuals in the reference population. The overall occurrence of VTE in patients and the reference group was 0.3% 0.2% at 90 days (P=0.56), 3.5% 0.7% at 1 year (P<0.001), 9.2% 2.2% at 3 years (P<0.001), and 18.7% and 3.9% at 5 years (P<0.001), respectively. The majority of cases represented PE. The overall mortality at 5 years was 44.4% 11.6% (P<0.001). No associations between patient characteristics and the occurrence of VTE during follow-up were detected.
Patients undergoing lung cancer surgery and who receive in-hospital medical thromboprophylaxis do not seem to be in high risk for symptomatic VTE during the early postoperative period. However, during long-term follow-up the occurrence of symptomatic VTE was significant.
肺癌切除术后静脉血栓栓塞症(VTE),包括深静脉血栓形成(DVT)和肺栓塞(PE)的发生率在文献中各不相同,关于血栓预防的最佳持续时间的证据有限。本研究旨在确定接受院内血栓预防并接受肺癌切除术的患者血栓栓塞并发症的早期和长期发生率。
该研究纳入了2004年至2016年在坦佩雷大学医院接受肺癌手术的所有患者。术后血栓预防在住院期间进行。VTE后续发作和生存的数据来自国家登记处。结果与人口统计学匹配的参考人群进行比较。
该研究包括435例患者和参考人群中的4338人。患者和参考组中VTE的总体发生率在90天时分别为0.3%和0.2%(P=0.56),1年时分别为3.5%和0.7%(P<0.001),3年时分别为9.2%和2.2%(P<0.001),5年时分别为18.7%和3.9%(P<0.001)。大多数病例为PE。5年时的总体死亡率分别为44.(此处原文有误,应为44.4%)4%和11.6%(P<0.001)。在随访期间未检测到患者特征与VTE发生之间的关联。
接受肺癌手术并接受院内药物血栓预防的患者在术后早期似乎没有发生有症状VTE的高风险。然而,在长期随访中,有症状VTE的发生率很高。